Items tagged with HIV coinfection
Pharmacokinetics of lopinavir/ritonavir super-boosting in infants and young children co-infected with HIV and TB (post)
Lopinavir/ritonavir (LPV/r) dosed at 1:1 ratio in the presence of rifampicin (RIF) was not inferior to LPV/r 4:1 ratio without rifampicin in HIV positive children in an interim pharmacokinetics (PK) analysis presented at the 7th International Workshop on HIV Paediatrics.
Death during MDR-TB treatment more likely in people with HIV and underweight or most drug-resistant patients (post)
People living with HIV, those who are underweight and those with more extensive drug resistance are more likely to die during treatment for multidrug-resistant tuberculosis (MDR-TB), a nine-country study has found. The findings were presented at the 46th Union World Conference on Lung Health in Cape Town last week.
Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in 19 low- and middle-income countries (post)
Three quarters of people with HIV/TB co-infection did not receive Xpert MTB/RIF testing for TB diagnosis between 2012 and 2014, according to a survey of cohorts in 19 low- and middle-income countries by the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium, presented by Dr Kate Clouse at the 46th Union World Conference on Lung Health in Cape Town from 2 to 6 December.
One in eight children with confirmed TB have drug-resistant TB in Cape Town (post)
One in eight children with confirmed TB have drug-resistant TB in Cape Town, South Africa, according to a surveillance study of childhood TB drug-resistance, presented by Professor Simon Schaaf at the 46th Union World Conference on Lung Health held in Cape Town from 2 to 6 December 2015.
LAM point-of-care TB testing reduces mortality in people with HIV/TB co-infection in hospital (post)
All-cause 8-week mortality is reduced by rapid point-of-care urine-based testing for tuberculosis (TB), using a test for detection of mycobacterial lipoarabinomannan (LAM) to guide rapid treatment initiation in hospitalised HIV-positive people with signs and symptoms of TB, according to a late-breaker study presented by Dr Jonny Peter of the University of Cape Town, and colleagues, at the 46th Union World Conference on Lung Health in Cape Town from 2 to 6 December 2015.
European Union Joint Action on HIV and Co-infection Prevention and Harm Reduction launched (post)
On 14-15 January 2016 in Vilnius, Lithuania, the European Union Joint Action on HIV and Co-infection Prevention and Harm Reduction (HA-REACT) held its first Partnership Forum to kick off activities. HA-REACT addresses existing gaps in the prevention of HIV and other co-infections, especially tuberculosis and viral hepatitis, among people who inject drugs. This is a three-year project which was launched in late 2015 with core funding from the European Union (EU), and is being implemented by 23 partners in 18 EU Member States. Twelve collaborating partners are contributing additional expertise, among them the European Centre for Disease Prevention and Control and the European Monitoring Centre for Drugs and Drug Addiction.
Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study (post)
Summary
PEPFAR releases technical considerations for country, regional HIV responses (post)
February 4, 2016 - With a focus on both scaled up goals and limited funding, PEPFAR released its Technical Considerations for COP/ROP 2016 this week, outlining strategies necessary to provide access to testing and effective treatment to more people immediately, while maintaining efforts to confront tuberculosis and deliver other essential prevention and health services.
Page 15 of 52 · Total posts: 0
←First 14 15 16 Last→